Autologous cell-coated particles for the treatment of segmental bone defects-a new cell therapy approach.
J Orthop Surg Res
; 14(1): 198, 2019 Jul 01.
Article
in En
| MEDLINE
| ID: mdl-31262323
ABSTRACT
BACKGROUND:
Adipose tissue-derived mesenchymal stem cells (AT-MSCs) are one of the most potent adult stem cells, capable of differentiating into bone, cartilage, adipose, muscle, and others. An innovative autologous AT-MSC-derived cell-based product (BonoFill-II) for bone tissue regeneration was developed to be suited as a bone graft for segmental bone defects.METHODS:
BonoFill-II was transplanted into 8 sheep with 3.2-cm full cortex segmental defect formed in the tibia. Bone regeneration was followed by X-ray radiographs for 12 weeks. At experiment termination, the healed tibia bones were analyzed by computed tomography, histology, and mechanical tests.RESULTS:
Our results indicate that one dose of BonoFill-II injectable formula led to an extensive bone growth within the transplantation site and to a complete closure of the critical gap in the sheep's tibia in a relatively short time (8-12 weeks), with no inflammation and no other signs of graft rejection. This new and innovative product opens new prospects for the treatment of long bone defects.CONCLUSIONS:
Injection of BonoFill-II (an innovative autologous cell therapy product for bone tissue regeneration) into a critical size segmental defect model (3.2 cm), generated in the sheep tibia, achieved full bridging of the gap in an extremely short period (8-12 weeks).Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Tibia
/
Transplantation, Autologous
/
Bone Regeneration
/
Mesenchymal Stem Cell Transplantation
/
Mesenchymal Stem Cells
Type of study:
Clinical_trials
Limits:
Animals
/
Female
/
Humans
Language:
En
Journal:
J Orthop Surg Res
Year:
2019
Document type:
Article
Affiliation country:
Israel